INS and hepatocellular carcinoma: Likewise, TZDs showed a similar trend in more beneficial effects against HCC incidence when compared with sulphonylurea (RR 0.47, 95% CI 0.22–0.97) and insulin (RR 0.30, 95% CI 0.14–0.61).